Clinical Research Directory

Inclusion Criteria: * Participants classified as seronegative or undetermined at baseline (by PRNT50 at baseline or anti-NS1 test Post-dose 3) that had received at least one dose of the tetravalent CYD dengue vaccine in the clinical sites of CYD15, CYD13, CYD29, CYD64, or CYD65 studies in Colombia * Informed consent form or Assent form has been signed and dated by the participant (based on local regulations), and/or informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations) * Participant (or participant and parent\[s\] or another legally acceptable representative) is (are) able to comply with all study procedures Exclusion criteria: * Participants that were withdrawn from the CYD15, CYD13, CYD29, CYD64, or CYD65 study in Colombia study due to "lost to follow-up" and despite various attempts, were not possible to be contacted * Participants that cannot be contacted after 3 phone calls, SMS, one home visit and written contact letter/email/WhatsApp The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.